D
Denis Bugnon
Researcher at University of Nantes
Publications - 36
Citations - 1071
Denis Bugnon is an academic researcher from University of Nantes. The author has contributed to research in topics: Gentamicin & Staphylococcus aureus. The author has an hindex of 19, co-authored 36 publications receiving 1035 citations. Previous affiliations of Denis Bugnon include University Hospital of Lausanne & University of Lausanne.
Papers
More filters
Journal ArticleDOI
In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time–kill curve methods
Cédric Jacqueline,Jocelyne Caillon,Virginie Le Mabecque,Anne-Françoise Miègeville,Pierre-Yves Donnio,Denis Bugnon,Gilles Potel +6 more
TL;DR: Linezolid plus rifampicin appeared to be the most active combination against methicillin-resistant S. aureus strains in time-kill experiments, and linezolid was antagonistic to the early bactericidal activity of gentamicin.
Journal ArticleDOI
In Vivo Efficacy of Ceftaroline (PPI-0903), a New Broad-Spectrum Cephalosporin, Compared with Linezolid and Vancomycin against Methicillin-Resistant and Vancomycin-Intermediate Staphylococcus aureus in a Rabbit Endocarditis Model
Cédric Jacqueline,Jocelyne Caillon,Virginie Le Mabecque,Anne-Françoise Miègeville,Antoine Hamel,Denis Bugnon,James Yigong Ge,Gilles Potel +7 more
TL;DR: Using the rabbit endocarditis model, ceftaroline exhibited superior bactericidal in vivo activity against resistant S. aureus strains and appeared to be the most effective drug against a heterogeneous glycopeptide-intermediate S.aureus strain.
Journal ArticleDOI
Prospective monitoring of cefepime in intensive care unit adult patients
Thomas M Chapuis,Eric Giannoni,Paul Majcherczyk,René Chioléro,Marie-Denise Schaller,Mette M. Berger,Saskia Bolay,Laurent A. Decosterd,Denis Bugnon,Philippe Moreillon +9 more
TL;DR: These empirical results confirm the suspected risks of hidden side-effects and inappropriate PK/PD parameters (for pathogens with upper-limit MICs) in a population of ICU adult patients and identifies a safety and efficacy window for cefepime doses of 2 g every 12 hours in patients with a CLCr infected by pathogens with cefEPime MICs ≤ 4 mg/l.
Journal ArticleDOI
In Vitro and In Vivo Synergistic Activities of Linezolid Combined with Subinhibitory Concentrations of Imipenem against Methicillin-Resistant Staphylococcus aureus
Cédric Jacqueline,Dominique Navas,Eric Batard,Anne-Françoise Miègeville,Virginie Le Mabecque,M. F. Kergueris,Denis Bugnon,Gilles Potel,Jocelyne Caillon +8 more
TL;DR: The combination of linezolid plus imipenem appears to be promising for the treatment of severe MRSA infections and merits further investigations to explore the mechanism underlying the synergy between the two drugs.
Journal ArticleDOI
Lung Distribution and Pharmacokinetics of Aerosolized Tobramycin
P. Le Conte,Gilles Potel,P Peltier,D Horeau,Jocelyne Caillon,M E Juvin,M. F. Kergueris,Denis Bugnon,D. Baron +8 more
TL;DR: Aminoglycosides are commonly used in the treatment of nosocomial pneumonia in association with beta-lactams andaerosolization of tobramycin produced high lung concentrations and low serum levels.